Using sophisticated digital-forward solutions to drive launch excellence

Increasingly, launch has become the No. 1 priority for many pharma companies, large and small. Investor statements mention terms like “exquisite launch,” “flawless launch” and “disrupted launch.” This is no surprise, as there has been extensive industry talk about how many launches are underperforming. From 2019 to 2021, about 60% of pharma launches did not meet analyst expectations. The numbers improved somewhat between 2022 and 2023, especially among larger companies: the latest estimate is only 40% to 50% have underperformed. Clearly, the industry still has a long way to go.

Having listened to leaders from more than 30 companies on the topic of why recent launches have underperformed, we can identify a number of consistent challenges—and opportunities—across the board:

But this is not a story of doom and gloom—it’s one of excitement, opportunity and bright spots. We believe there is a significant opportunity to more effectively and efficiently set each product in motion to achieve its highest return. Much of that opportunity lies in being “digitally forward” at launch.

What does it mean to be digitally forward at launch?

The word “digital” is perhaps one of the most misused (and overused) words of our time. In launch, many use digital to mean “non-personal channel.” It suggests an air of “efficiency” and “cheap” and “lean.” But digital solutions can add value years before an actual launch. We believe digital can drive two separate but important goals: launch sophistication for maximizing an individual launch and launch efficiency to drive scale across all launches.

FIGURE 1: Launching well requires investment in both sophistication and scale

In this article we will share a perspective on what it means to deliver digitally forward launches and drive launch sophistication.

Creating more sophistication in drug launches

One of the ways we can use digital to advance launch is by using it to make launch better—increasing the sophistication in how we approach the market, accelerate customer learning, personalize engagement and service and measure success.

While every launch is different, there is a consistent set of “jobs to be done” that the best launches do well. The most common place for digital innovation is in orchestrating the experience, but there is an opportunity to use digitally forward solutions in each of these jobs to accomplish a more precise and accelerated outcome:

FIGURE 2: Opportunities for digitally forward ZS solutions across the launch

Each launch is different; some may warrant all of these, some may need fewer. In a previous analysis, ZS analyzed 96 recent pharma launches to determine the market factors that had the most impact on product success and strategy. Unmet need is one of the most critical factors driving different success strategies at launch, both in terms of whether the unmet need is clear or marketing shaping is required and in terms of how much clinical differentiation the product is offering to address unmet need that does exist. Archetyping launches based on these dimensions determines which strategic priorities are most critical and can guide digitally forward investments

FIGURE 3: Investment in brand solutions should be driven by the market shaping required, clinical differentiation and the overlap with existing customers

Let’s look at two examples where companies used technology and AI in product-specific solutions to make launch better and saw positive impact in their ability to impact patient care, exceeding forecasts in the first year.

For example, a recent rare disease launch with high unmet need and low competition (Figure 4) used digitally forward solutions from ZS to drive multiple launch objectives. They used a digital front door to streamline patient care, used AI to predict early adopters and who would have relevant patients and fed all of that into dynamic targeting that made predictions and recommendations for how reps and other channels should be orchestrated based on where the eligible patients were in the ecosystem. They had a high-touch patient support program and used AI to analyze call center data and conversations with nurse navigators and recommended personal support interventions.

FIGURE 4: Examples of new and innovative, high unmet need, low customer readiness

Examples of new and innovative, high unmet need, low customer readiness

Another product was in an established, competitive market with only moderate unmet need, but it was clinically differentiated from several existing biologic therapies (Figure 5). This launch team used primary research and AI to predict individual physicians’ needs and preferences, customized their messages and content for those needs and deployed a combination of 10 digital channels based on customer preferences that they orchestrated to align with commercial and medical in-field teams. They also used digital tools to optimize gross to net at a payer level and promoted payer wins to the relevant customers as soon as they occurred.

FIGURE 5: Examples of clear win, moderate unmet need, high clinical differentiation

Where pharma can start to drive sophistication at scale

Driving sophisticated launch requires engagement from multiple functions: marketing, medical, market access, insights and analytics. By breaking the objectives apart into sophistication versus scale, each function can focus more on a clear, achievable objective and work together to drive the dual desired outcome.

To create more sophisticated and better-performing launches, companies can take these first steps:

Companies that are “always in launch mode” have an opportunity to build digital capabilities that enable these solutions at scale. Much of this done through an IT function, though launch excellence functions can also have a critical role. Our next article will focus on ZS’s digitally forward solutions that drive scale.

Watch our webinar to find out how to create more sophisticated and better-performing launches.

Add insights to your inbox

We’ll send you content you’ll want to read – and put to use.
Sign me up
/content/zs/en/forms/subscription-preferences
default

Meet our experts

left
white
Eyebrow Text
Button CTA Text
#
primary
default
default
tagList
/content/zs/en/insights

/content/zs/en/insights

zs:topic/strategy-&-advisory,zs:topic/marketing,zs:topic/sales,zs:topic/portfolio-pipeline,zs:topic/value-&-access,zs:topic/emerging-biopharma,zs: